Jean Bennett, MD, PhD, inventor and co-developer of Luxturna, the first FDA-approved gene therapy, now serves as scientific co-founder and sits on the board of Opus Genetics, founded to investigate gene therapies for rare retinal diseases.
Bennett is aiming to use gene therapies to treat ultra-rare diseases with the goal of eventually targeting diseases with more prevalence in the population.
Healio/OSN spoke with Bennett about her career investigating gene therapies and what she sees for the future of Opus Genetics.
Healio/OSN: How did you get started investigating gene therapies?
Bennett: I